Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

Trial Identifier: D9281R00003
Sponsor: AstraZeneca
Start Date: December 2025
Primary Completion Date: December 2029
Study Completion Date: December 2029

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russia Kazan, Russia
Russia Novosibirsk, Russia